Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Blueprint Medi Cm ST (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 2,436,394
  • Shares Outstanding, K 39,120
  • Annual Sales, $ 27,770 K
  • Annual Income, $ -72,500 K
  • 36-Month Beta 1.23
  • Price/Sales 87.99
  • Price/Cash Flow 0.00
  • Price/Book 6.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.48 +33.99%
on 08/23/17
64.98 -4.16%
on 09/19/17
+14.51 (+30.37%)
since 08/22/17
3-Month
41.41 +50.40%
on 08/21/17
64.98 -4.16%
on 09/19/17
+14.49 (+30.32%)
since 06/22/17
52-Week
25.08 +148.33%
on 12/07/16
64.98 -4.16%
on 09/19/17
+33.17 (+113.95%)
since 09/22/16

Most Recent Stories

More News
Stocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and Cytokinetics

If you want a Stock Review on AVIR, BPMC, CALA, or CYTK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, September 20, 2017, the...

AVIR : 0.65 (+4.00%)
CYTK : 14.30 (+0.70%)
BPMC : 62.28 (-0.29%)
CALA : 15.90 (-1.85%)
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated data from its ongoing...

BPMC : 62.28 (-0.29%)
Blueprint Medicines to Present at Morgan Stanley 15th Annual Global Healthcare Conference

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that Jeff Albers,Blueprint...

MS : 48.22 (-0.08%)
BPMC : 62.28 (-0.29%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Versartis Inc (VSAR, BPMC, ARRY, ALDR, FLXN)

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

VSAR : 2.67 (-87.62%)
ARRY : 11.32 (-1.31%)
ALDR : 10.85 (+3.83%)
BPMC : 62.28 (-0.29%)
FLXN : 25.81 (-3.26%)
Blueprint Medici is Among the Companies in the Biotechnology Industry with the Best Relative Performance (BPMC, ZIOP, PTCT, INSM, IONS)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

PTCT : 18.52 (-7.63%)
IONS : 51.32 (-0.98%)
ZIOP : 6.17 (+1.82%)
BPMC : 62.28 (-0.29%)
INSM : 28.50 (-1.18%)
Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that updated data from its...

BPMC : 62.28 (-0.29%)
Stock Performance Review on Biotech Industry -- Blueprint Medicines, Calithera Biosciences, Concordia Intl., and Cytokinetics

If you want a Stock Review on BPMC, CALA, CXRX, or CYTK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, the NASDAQ Composite ended...

CYTK : 14.30 (+0.70%)
CXRX : 1.21 (-2.42%)
BPMC : 62.28 (-0.29%)
CALA : 15.90 (-1.85%)
Featured Company News - Galena Biopharma Announces Merger Agreement with SELLAS Life Sciences Group

Research Desk Line-up: Blueprint Medicines Post Earnings Coverage

GALE : 0.35 (unch)
BPMC : 62.28 (-0.29%)
25.7% Return Seen to Date on SmarTrend Blueprint Medici Call (BPMC)

SmarTrend identified an Uptrend for Blueprint Medici (NASDAQ:BPMC) on June 16th, 2017 at $39.29. In approximately 2 months, Blueprint Medici has returned 25.73% as of today's recent price of $49.40.

BPMC : 62.28 (-0.29%)
Blueprint Medicines Reports Second Quarter 2017 Financial Results

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided...

BPMC : 62.28 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Support & Resistance

2nd Resistance Point 63.84
1st Resistance Point 63.06
Last Price 62.28
1st Support Level 61.34
2nd Support Level 60.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.